



gil87d

Food and Drug Administration
Minneapolis District
240 Hennepin Avenue
Minneapolis MN 55401-1999
Telephone: 612-334-4100

April 25, 2001

WARNING LETTER

CERTIFIED MAIL
RETURN RECEIPT REQUESTED

Refer to MIN 01 - 55

James A. Bose
President
Lime Creek Ag Services, Inc.
17 Country Lane, P.O. Box 440
Fulda, Minnesota 56131

Dear Mr. Bose:

On March 14, 2001, a representative of the State of Minnesota acting on behalf of the Food and Drug Administration (FDA) inspected your animal feed manufacturing operation located at 17 Country Lane, Fulda, MN. This inspection found significant deviations from the requirements set forth in Title 21, Code of Federal Regulations, Part 589.2000, "Animal Proteins Prohibited in Ruminant Feed" (21 CFR 589.2000). The regulation is intended to prevent the establishment and amplification of Bovine Spongiform Encephalopathy (BSE). Such deviations cause products being manufactured and/or distributed by this facility to be adulterated and misbranded within the meaning of Sections 402(a)(2)(C)(i), 402(a)(4) and 403(f) of the Federal Food, Drug and Cosmetic Act (the Act).

Our investigation found a failure to label your products with the required cautionary statement, "Do Not Feed to Cattle or Other Ruminants." The FDA suggests the statement be distinguished by different type size or color or other means of highlighting the statement so that it is easily noticed by a purchaser.

The investigation found other deviations from 21 CFR 589.2000 including failure to maintain a label of a feed containing an animal protein and failure to establish and implement procedures for handling prohibited material.

The above is not intended to be an all-inclusive list of deviations from the regulations. As a manufacturer of materials intended for animal feed use, you are responsible for ensuring that your overall operation and the products you manufacture and distribute are in compliance with the law. We have enclosed a

Page Two

James A. Bose
April 25, 2001

copy of the FDA's Small Entity Compliance Guide to assist you with complying with the regulation.

You should take prompt action to correct these violations and you should establish a system whereby such violations do not recur. Failure to promptly correct these violations may result in regulatory and/or administrative sanctions. These sanctions include, but are not limited to, seizure and/or injunction.

We have received your letter dated March 15, 2001, which discussed your plans to correct the deficiencies noted during the March 14, 2001, inspection. If properly implemented, those corrective actions appear to be adequate. They will be assessed during a future inspection.

Please provide this office a written update within 15 working days of receipt of this letter with the steps you have taken to bring your firm into compliance with the law. Your response should include an explanation of each step being taken to correct the violations and prevent their recurrence. If corrective action cannot be taken within 15 working days, state the reason for the delay and the date by which the corrections will be completed. Please include copies of any available documentation demonstrating that corrections have been made.

Your reply should be directed to Compliance Officer Timothy G. Philips at the address indicated on the letterhead.

Sincerely,


Cheryl A. Bigham
Acting Director
Minneapolis District

TGP/ccl

Enclosures: FDA-483, 3/14/01
FDA Small Entities Compliance Guide, 21 CFR 589.2000